BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 25562146)

  • 1. Diffusion of molecular diagnostic lung cancer tests: a survey of german oncologists.
    Steffen JA
    J Pers Med; 2014 Mar; 4(1):102-14. PubMed ID: 25562146
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diffusion kurtosis imaging: correlation analysis of quantitative model parameters with molecular features in advanced lung adenocarcinoma.
    Peng Q; Tang W; Huang Y; Wu N; Yang L; Li N
    Chin Med J (Engl); 2020 Oct; 133(20):2403-2409. PubMed ID: 32960838
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Concomitant echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase rearrangement and epidermal growth factor receptor mutation in non-small cell lung cancer patients from eastern India.
    Mohapatra PR; Sahoo S; Bhuniya S; Panigrahi MK; Majumdar SKD; Mishra P; Patra S
    J Cancer Res Ther; 2020; 16(4):850-854. PubMed ID: 32930129
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epidermal Growth Factor Receptor Mutation (EGFR) Testing for Prediction of Response to EGFR-Targeting Tyrosine Kinase Inhibitor (TKI) Drugs in Patients with Advanced Non-Small-Cell Lung Cancer: An Evidence-Based Analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2010; 10(24):1-48. PubMed ID: 23074402
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting the MET gene for the treatment of non-small-cell lung cancer.
    Gelsomino F; Facchinetti F; Haspinger ER; Garassino MC; Trusolino L; De Braud F; Tiseo M
    Crit Rev Oncol Hematol; 2014 Feb; 89(2):284-99. PubMed ID: 24355409
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patterns of epidermal growth factor receptor testing across 111 tertiary care centers in India: Result of a questionnaire-based survey.
    Prabhash K; Parikh PM; Rajappa SJ; Noronha V; Joshi A; Aggarwal S; Bondarde S; Patil S; Desai C; Dattatreya PS; Naik R; Anand S; Chacko RT; Biswas G; Sahoo TP; Dabkara D; Patil V; Chandrakant MV; Das PK; Vaid AK; Doval DC
    South Asian J Cancer; 2018; 7(3):203-206. PubMed ID: 30112342
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anaplastic Lymphoma Kinase Testing: IHC vs. FISH vs. NGS.
    Niu X; Chuang JC; Berry GJ; Wakelee HA
    Curr Treat Options Oncol; 2017 Nov; 18(12):71. PubMed ID: 29143897
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biopsy Procedures and Molecular Testing Utilization and Related Costs in Patients with Metastatic Lung Cancer.
    Shinde R; Cao X; Kothari S
    J Manag Care Spec Pharm; 2016 Oct; 22(10):1194-203. PubMed ID: 27668568
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Comparative Study of Cell Block versus Biopsy for Detection of Epidermal Growth Factor Receptor Mutations and Anaplastic Lymphoma Kinase Rearrangement in Adenocarcinoma Lung.
    Gupta V; Shukla S; Husain N; Kant S; Garg R
    J Cytol; 2019; 36(1):13-17. PubMed ID: 30745733
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology.
    Lindeman NI; Cagle PT; Beasley MB; Chitale DA; Dacic S; Giaccone G; Jenkins RB; Kwiatkowski DJ; Saldivar JS; Squire J; Thunnissen E; Ladanyi M
    Arch Pathol Lab Med; 2013 Jun; 137(6):828-60. PubMed ID: 23551194
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of clinical and radiological characteristics between anaplastic lymphoma kinase rearrangement and epidermal growth factor receptor mutation in treatment naïve advanced lung adenocarcinoma.
    Miao Y; Zhu S; Li H; Zou J; Zhu Q; Lv T; Song Y
    J Thorac Dis; 2017 Oct; 9(10):3927-3937. PubMed ID: 29268403
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Standard technical specifications for methacholine chloride (Methacholine) bronchial challenge test (2023)].
    ; ;
    Zhonghua Jie He He Hu Xi Za Zhi; 2024 Feb; 47(2):101-119. PubMed ID: 38309959
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epidermal growth factor receptor tyrosine kinase (EGFR-TK) mutation testing in adults with locally advanced or metastatic non-small cell lung cancer: a systematic review and cost-effectiveness analysis.
    Westwood M; Joore M; Whiting P; van Asselt T; Ramaekers B; Armstrong N; Misso K; Severens J; Kleijnen J
    Health Technol Assess; 2014 May; 18(32):1-166. PubMed ID: 24827857
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Precision medicine in NSCLC and pathology: how does ALK fit in the pathway?
    Kerr KM; López-Ríos F
    Ann Oncol; 2016 Sep; 27 Suppl 3():iii16-iii24. PubMed ID: 27573752
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regional reporting of the incidence of Anaplastic Lymphoma Kinase mutation in 379 non-small-cell lung cancer patients from Kolkata: Using immunohistochemistry as the diagnostic modality in a significant subset.
    Chatterjee K; Bhowmik R; Chattopadhyay B
    South Asian J Cancer; 2017; 6(4):169-170. PubMed ID: 29404296
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular testing for selection of patients with lung cancer for epidermal growth factor receptor and anaplastic lymphoma kinase tyrosine kinase inhibitors: American Society of Clinical Oncology endorsement of the College of American Pathologists/International Association for the study of lung cancer/association for molecular pathology guideline.
    Leighl NB; Rekhtman N; Biermann WA; Huang J; Mino-Kenudson M; Ramalingam SS; West H; Whitlock S; Somerfield MR
    J Clin Oncol; 2014 Nov; 32(32):3673-9. PubMed ID: 25311215
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Validity of Natural Language Processing for Ascertainment of
    Goulart BHL; Silgard ET; Baik CS; Bansal A; Sun Q; Durbin EB; Hands I; Shah D; Arnold SM; Ramsey SD; Kavuluru R; Schwartz SM
    JCO Clin Cancer Inform; 2019 May; 3():1-15. PubMed ID: 31058542
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted therapy for lung cancer: Beyond EGFR and ALK.
    Herrera-Juárez M; Serrano-Gómez C; Bote-de-Cabo H; Paz-Ares L
    Cancer; 2023 Jun; 129(12):1803-1820. PubMed ID: 37073562
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.